Jennifer Java
Nurse Practitioner · Anaheim, CANPI 1053046912
Payments from drug & device makers
Across 706 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$961
- plus $5K from 21 others
What the payments were for
- Food & beverage$14,454100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 107 | $2,350 |
| Johnson & Johnson | 62 | $2,004 |
| Teva Pharmaceuticals USA, Inc. | 85 | $1,809 |
| Neurocrine Biosciences, Inc. | 51 | $1,299 |
| Alkermes, Inc. | 45 | $1,007 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 72 | $961 |
| Lundbeck LLC | 40 | $689 |
| Otsuka America Pharmaceutical, Inc. | 31 | $686 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $541 |
| Noven Therapeutics, LLC | 24 | $476 |
| Almatica Pharma LLC | 25 | $424 |
| Axsome Therapeutics, Inc. | 21 | $423 |
| Idorsia Pharmaceuticals US Inc | 21 | $301 |
| E.r. Squibb & Sons, L.L.C. | 12 | $297 |
| Corium, LLC | 14 | $280 |
| Ironshore Pharmaceuticals Inc. | 16 | $254 |
| Sunovion Pharmaceuticals Inc. | 7 | $184 |
| Indivior Inc. | 10 | $182 |
| Vanda Pharmaceuticals Inc. | 3 | $64 |
| Collegium Pharmaceutical, Inc. | 4 | $59 |
| Tris Pharma Inc | 2 | $49 |
| Noven Pharmaceuticals, Inc. | 2 | $39 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Neos Therapeutics, LP | 1 | $20 |
| Biogen | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Brainsway USA Inc | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$422
- VRAYLAR$369
- INVEGA SUSTENNA$249
- INVEGA TRINZA$249
- INGREZZA$128
- UZEDY$121
- Austedo XR$117
How this compares
$14,466 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 27 | $188,455 |
| VraylarCariprazine Hcl | 23 | $30,677 |
| Invega SustennaPaliperidone Palmitate | 12 | $28,322 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $14,224 |
| Aripiprazole | 82 | $12,914 |
| TrintellixVortioxetine Hydrobromide | 15 | $7,171 |
| DayvigoLemborexant | 12 | $5,325 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 34 | $3,129 |
| Quetiapine Fumarate | 142 | $1,814 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 29 | $1,774 |
| Trazodone Hcl | 85 | $1,738 |
| Bupropion XlBupropion Hcl | 102 | $1,181 |
| Buspirone Hcl | 117 | $1,019 |
| Divalproex Sodium ErDivalproex Sodium | 45 | $982 |
| Duloxetine Hcl | 84 | $926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,809 | $188,45527 claims |
| AbbVieVraylar | $2,350 | $30,67723 claims |
| Johnson & JohnsonInvega Sustenna | $2,004 | $28,32212 claims |
| Axsome Therapeutics, Inc.Auvelity | $423 | $14,22411 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $541 | $7,17115 claims |
| Almatica Pharma LLCSertraline Hcl | $424 | $27556 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Anaheim
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.